TY - JOUR
T1 - Characteristics and outcome of congenital mesoblastic nephroma
T2 - A report of 376 patients registered in the SIOP 93-01, SIOP WT 2001, UK-IMPORT, and AIEOP protocols
AU - Quarello, Paola
AU - Dandis, Rana
AU - Chowdhury, Tanzina
AU - Verschuur, Arnauld
AU - Brok, Jesper
AU - Vujanic, Gordan
AU - Vokuhl, Christian
AU - Collini, Paola
AU - Coulomb, Aurore
AU - Serra, Annalisa
AU - Biasoni, Davide
AU - Flores, Paula
AU - Kager, Leo
AU - Segers, Heidi
AU - Tudor, Karolina Malić
AU - Burman, Marta Maria
AU - dos Reis Farinha, Nuno Jorge
AU - Romerius, Patrik
AU - Godzinski, Jan
AU - van Grotel, Martine
AU - Ramirez-Villar, Gema Lucia
AU - De Camargo, Beatriz
AU - Furtwängler, Rhoikos
AU - Al-Saadi, Reem
AU - Van Tinteren, Harm
AU - Graf, Norbert
AU - Spreafico, Filippo
AU - van den Heuvel-Eibrink, Marry
N1 - Publisher Copyright:
© 2026 Quarello et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
PY - 2026/5
Y1 - 2026/5
N2 - Background Congenital mesoblastic nephroma (CMN) is the most common renal neoplasm diagnosed in the very first months of life. Complete nephrectomy only is the gold standard treatment. Objectives and methods This retrospective study aimed to explore the characteristics and outcome of CMN patients registered in the SIOP 93–01, SIOP WT 2001, UK-IMPORT, and AIEOP studies (1993–2019). Results A total of 376 CMN cases were identified, with a median age at diagnosis of 28 days. Stage information was available for 337 patients: 92/337 (27.4%) were diagnosed with stage I, 177/337 (52.6%) with stage II, and 67/337 (20%) with stage III. Among 272 patients with available histological data, 113/272 (41.5%) had classic, 105/272 (38.6%) cellular, and 54/272 (19.9%) mixed subtype. Treatment details were available for 314 patients; 248 (79%) underwent initial surgery, and 66 (21%) received preoperative chemotherapy. Among the latter group, 60% of patients showed a measurable reduction in tumor volume, indicating a favorable response to chemotherapy. The 5-year event-free survival rate was 93.8%, and the overall survival rate was 96.9%. The cumulative 5-year incidence of relapse was 5.3%, with a median time to recurrence of 4 months. Of the 16 relapse cases, 8 were in the cellular subtype, 5 in the mixed subtype, and 3 in the classical subtype. Conclusions This study confirms that CMN patients have an excellent outcome, with complete surgical resection being curative in the majority of cases. Chemosensitivity is observed in a significant proportion, suggesting that neoadjuvant chemotherapy may be a viable option in selected cases. While age at diagnosis, histological subtype, and survival outcomes are consistent with previous reports, we highlight that recurrences, though infrequent, tend to occur early and are not restricted to the cellular subtype. Further prospective studies and molecular investigations are required to refine clinical management strategies and update treatment recommendations.
AB - Background Congenital mesoblastic nephroma (CMN) is the most common renal neoplasm diagnosed in the very first months of life. Complete nephrectomy only is the gold standard treatment. Objectives and methods This retrospective study aimed to explore the characteristics and outcome of CMN patients registered in the SIOP 93–01, SIOP WT 2001, UK-IMPORT, and AIEOP studies (1993–2019). Results A total of 376 CMN cases were identified, with a median age at diagnosis of 28 days. Stage information was available for 337 patients: 92/337 (27.4%) were diagnosed with stage I, 177/337 (52.6%) with stage II, and 67/337 (20%) with stage III. Among 272 patients with available histological data, 113/272 (41.5%) had classic, 105/272 (38.6%) cellular, and 54/272 (19.9%) mixed subtype. Treatment details were available for 314 patients; 248 (79%) underwent initial surgery, and 66 (21%) received preoperative chemotherapy. Among the latter group, 60% of patients showed a measurable reduction in tumor volume, indicating a favorable response to chemotherapy. The 5-year event-free survival rate was 93.8%, and the overall survival rate was 96.9%. The cumulative 5-year incidence of relapse was 5.3%, with a median time to recurrence of 4 months. Of the 16 relapse cases, 8 were in the cellular subtype, 5 in the mixed subtype, and 3 in the classical subtype. Conclusions This study confirms that CMN patients have an excellent outcome, with complete surgical resection being curative in the majority of cases. Chemosensitivity is observed in a significant proportion, suggesting that neoadjuvant chemotherapy may be a viable option in selected cases. While age at diagnosis, histological subtype, and survival outcomes are consistent with previous reports, we highlight that recurrences, though infrequent, tend to occur early and are not restricted to the cellular subtype. Further prospective studies and molecular investigations are required to refine clinical management strategies and update treatment recommendations.
UR - https://www.scopus.com/pages/publications/105040027060
U2 - 10.1371/journal.pone.0349345
DO - 10.1371/journal.pone.0349345
M3 - Article
AN - SCOPUS:105040027060
SN - 1932-6203
VL - 21
JO - PloS one
JF - PloS one
IS - 5 May
M1 - e0349345
ER -